Taiwan Stock Exchange · Healthcare
Tanvex BioPharma stock from India: price, numbers and tax
Tanvex BioPharma (6541) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Tanvex BioPharma at a glance
- Price
- NT$28.10+NT$0.05 (0.18%)
- Market cap
- NT$7.45B
- Day range
- NT$27.50 – NT$28.60
- P/E
- -4.67
- Dividend yield
- None
- Volume
- 402.76K
- 1 month
- -7.72%
- 6 months
- -26.73%
- YTD
- -48.91%
- 1 year
- -49.37%
- 5 years
- -80.69%
Tanvex BioPharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$401.0M | NT$34.7M | NT$61.4M | NT$22.4M | NT$5.4M |
| Gross profit | −NT$440.7M | NT$8.3M | NT$59.7M | −NT$19.3M | NT$3.5M |
| Operating income | −NT$1.4B | −NT$1.4B | −NT$2.1B | −NT$1.6B | −NT$1.5B |
| Net income | −NT$1.5B | −NT$1.4B | −NT$2.1B | −NT$1.6B | −NT$1.5B |
| Earnings per share | −NT$6.13 | −NT$8.90 | −NT$16.42 | −NT$13.55 | −NT$13.80 |
| EBITDA | −NT$1.0B | −NT$1.0B | −NT$1.8B | −NT$1.3B | −NT$1.3B |
| Total assets | NT$8.0B | NT$2.7B | NT$2.8B | NT$3.4B | NT$4.7B |
| Total debt | NT$1.6B | NT$1.6B | NT$1.7B | NT$1.8B | NT$1.8B |
| Cash and short-term investments | NT$878.7M | NT$377.0M | NT$380.8M | NT$786.2M | NT$2.2B |
| Shareholders' equity | NT$5.7B | NT$893.3M | NT$821.1M | NT$1.4B | NT$2.8B |
| Operating cash flow | −NT$1.0B | −NT$1.2B | −NT$1.4B | −NT$1.3B | −NT$1.4B |
| Free cash flow | −NT$1.7B | −NT$1.3B | −NT$1.5B | −NT$1.4B | −NT$1.4B |
| Capital expenditure | −NT$670.2M | −NT$110.8M | −NT$71.3M | −NT$96.1M | −NT$30.3M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| YungShin Global | 3705.TW | NT$58.80 | NT$15.66B |
| ScinoPharm Taiwan | 1789.TW | NT$19.70 | NT$15.58B |
| Excelsior Medical | 4104.TW | NT$72.00 | NT$13.56B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Tanvex BioPharma from India
What Tanvex BioPharma does
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Tanvex BioPharma operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
How are Tanvex BioPharma dividends taxed for Indian investors?
Tanvex BioPharma trades on the Taiwan Stock Exchange but is domiciled in Cayman Islands, so any withholding on its dividends follows that country's rules rather than those of Taiwan. Dividends are taxed at your slab rate in India.
What tax do I pay in India when I sell Tanvex BioPharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.